| Year |
Citation |
Score |
| 2020 |
Luo* J, Meng J, Messing EM, Joseph JV, Yeh S, Chang C. MP79-14 LNCRNA-P21 ALTERS THE ANTIANDROGEN ENZALUTAMIDE-INDUCED PROSTATE CANCER NEUROENDOCRINE DIFFERENTIATION VIA MODULATING THE EZH2/STAT3 SIGNALING The Journal of Urology. 203: e1221. DOI: 10.1097/Ju.0000000000000971.014 |
0.328 |
|
| 2020 |
Sathianathen N, Gantz* J, Alarid-Escudero F, Kuntz K, Lawrentschuk N, Konety B, Messing E. MP73-07 INTRAVESICAL CHEMOTHERAPY FOR LOW GRADE BLADDER CANCER The Journal of Urology. 203: e1123-e1124. DOI: 10.1097/Ju.0000000000000959.07 |
0.323 |
|
| 2019 |
Jubber I, Shariat SF, Conroy S, Tan WS, Gordon PC, Lotan Y, Messing EM, Stenzl A, Rhijn BV, Kelly JD, Catto JWF, Cumberbatch MG. Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. European Urology. PMID 31791622 DOI: 10.1016/J.Eururo.2019.10.010 |
0.32 |
|
| 2019 |
Chen J, Chou F, Yeh S, Ou Z, Shyr C, Huang C, Xiang Z, Sun Y, Messing E, Zu X, Chang C. Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated Gαi protein/MAPK/MMP9 intracellular signaling. Oncogene. PMID 31506605 DOI: 10.1038/S41388-019-0964-6 |
0.319 |
|
| 2019 |
Huang CP, Chen J, Chen CC, Liu G, Zhang Y, Messing E, Yeh S, Chang C. ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals. Journal of Experimental & Clinical Cancer Research : Cr. 38: 275. PMID 31234917 DOI: 10.1186/S13046-019-1258-0 |
0.31 |
|
| 2019 |
Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG. Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900107. PMID 31216227 DOI: 10.1200/Jco.19.00107 |
0.305 |
|
| 2019 |
Lotan Y, Inman BA, Davis LG, Kassouf W, Messing E, Daneshmand S, Canter D, Marble HT, Joseph AM, Jewell S, Boorjian SA. Evaluation of the UroVysion™ Test to Predict Recurrence and/or Progression of Disease After BCG for Primary High Grade Non-Muscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial. The Journal of Urology. 101097JU000000000000. PMID 31120373 DOI: 10.1097/Ju.0000000000000355 |
0.313 |
|
| 2019 |
Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ, Sankin AI, Schoenberg MP, Shipley WU, Villers A, Efstathiou JA, Bellmunt J, et al. SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World Journal of Urology. PMID 30684034 DOI: 10.1007/S00345-018-2606-Y |
0.32 |
|
| 2019 |
Witthaus M, Truong* M, Gantz J, Frye T, Ghazi A, Messing E, Joseph J, Miyamoto H, Rashid H. MP24-15 MR/US FUSION TARGETED BIOPSY FAILED TO DETECT PROSTATE CANCER: ROLE OF CONFIRMMDX® AS AN ADJUNCT Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555640.83324.73 |
0.31 |
|
| 2019 |
Truong* M, Kadiyala V, Osinksi T, Steinmetz A, Yang Z, Hollenberg G, Weinberg E, Feng C, Messing E, Miyamoto H, Frye T. PD17-12 FREQUENCY OF DOWNGRADING FROM MR/US FUSION BIOPSY TO RADICAL PROSTATECTOMY BASED ON ISUP 2014 GRADING MODIFICATIONS Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555572.16084.D2 |
0.332 |
|
| 2019 |
Song W, Xu* H, Doersch KM, Chou F, He D, Chen Y, Hsu I, Yeh C, Chang LS, Li L, Messing E, Chang C, Yeh S. MP16-04 TARGETING NEWLY IDENTIFIED ERβ/TGF-β1/SMAD3 SIGNALS WITH THE FDA-APPROVED ANTI-ESTROGEN FASLODEX OR AN ERβ SELECTIVE ANTAGONIST IN RENAL CELL CARCINOMA Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555340.89148.9F |
0.305 |
|
| 2019 |
Lee* Z, Jegede O, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MA, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. MP14-18 AN ANATOMIC CLASSIFICATION SYSTEM FOR LOCAL RECURRENCE FOLLOWING RESECTION OF INTERMEDIATE AND HIGH RISK NON-METASTATIC RENAL CELL CARCINOMA: AN ANALYSIS OF THE ASSURE (ECOG-ACRIN 2805) TRIAL Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555314.30838.23 |
0.332 |
|
| 2018 |
Wu CH, Silvers CR, Messing EM, Lee YF. Bladder cancer extracellular vesicles drive tumorigenesis by inducing the unfolded protein response in endoplasmic reticulum of non-malignant cells. The Journal of Biological Chemistry. PMID 30593508 DOI: 10.1074/Jbc.Ra118.006682 |
0.349 |
|
| 2018 |
Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, et al. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. Jama. 319: 1880-1888. PMID 29801011 DOI: 10.1001/Jama.2018.4657 |
0.323 |
|
| 2018 |
Truong M, Frye T, Messing E, Miyamoto H. Historical and contemporary perspectives on cribriform morphology in prostate cancer. Nature Reviews. Urology. PMID 29713007 DOI: 10.1038/S41585-018-0013-1 |
0.341 |
|
| 2018 |
Truong M, Weinberg E, Hollenberg G, Borch M, Park JH, Gantz J, Feng C, Frye T, Ghazi A, Wu G, Joseph J, Rashid H, Messing E. Institutional Learning Curve Associated with Implementation of a Magnetic Resonance/Transrectal Ultrasound Fusion Biopsy Program Using PI-RADS™ Version 2: Factors that Influence Success Urology Practice. 5: 69-75. DOI: 10.1016/J.Urpr.2016.11.007 |
0.335 |
|
| 2018 |
Lotan Y, Messing E, Inman B, Daneshmand S, Kassouf W, Canter D, Marble T, Joseph A, Boorjian SA. MP08-14 EVALUATION OF THE UROVYSION™ TEST FOR PREDICTING RECURRENCE AND PROGRESSION IN PATIENTS RECEIVING BCG FOR HIGH GRADE NON-MUSCLE INVASIVE BLADDER CANCER Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.319 |
0.306 |
|
| 2018 |
Liu Y, Lee Y, Yin P, Messing E. MP65-18 BLADDER CANCER EXTRACELLULAR VESICLES FACILITATE METASTASIS Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2084 |
0.331 |
|
| 2017 |
Silvers CR, Miyamoto H, Messing EM, Netto GJ, Lee YF. Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer. Oncotarget. 8: 91199-91208. PMID 29207636 DOI: 10.18632/Oncotarget.20043 |
0.367 |
|
| 2017 |
Nguyen HG, Welty C, Lindquist K, Ngo V, Gilbert E, Bengtsson H, Magi-Galluzzi C, Jean-Gilles J, Yao J, Cooperberg M, Messing E, Klein EA, Carroll PR, Paris PL. Validation of GEMCaP as a DNA based biomarker to predict prostate cancer recurrence after radical prostatectomy. The Journal of Urology. PMID 28941923 DOI: 10.1016/J.Juro.2017.09.071 |
0.34 |
|
| 2017 |
Truong M, Feng C, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP. A Comprehensive Analysis of Cribriform Morphology on MR/US Fusion Biopsy Correlated with Radical Prostatectomy Specimens. The Journal of Urology. PMID 28728994 DOI: 10.1016/J.Juro.2017.07.037 |
0.339 |
|
| 2017 |
Ristau BT, Manola J, Haas NB, Heng DYC, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo RG. Retroperitoneal Lymphadenectomy in High-Risk Non-Metastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. The Journal of Urology. PMID 28728992 DOI: 10.1016/J.Juro.2017.07.042 |
0.3 |
|
| 2017 |
Truong M, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP. Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric MRI: Correlation with Final Histopathology. The Journal of Urology. PMID 28163032 DOI: 10.1016/J.Juro.2017.01.077 |
0.33 |
|
| 2017 |
Nguyen HG, Welty C, Lindquist K, Ngo V, Gilbert E, Bengtsson H, Magi-Galluzzi C, Jean-Gilles J, Yao J, Cooperberg MR, Messing EM, Klein EA, Carroll P, Paris P. Validation of GEMCaP as a DNA based biomarker to predict disease recurrence in patients undergoing prostatectomy for prostate cancer. Journal of Clinical Oncology. 35: 58-58. DOI: 10.1200/Jco.2017.35.6_Suppl.58 |
0.328 |
|
| 2017 |
Kilari D, Guancial E, Sahasrabudhe D, Bylow K, Sievert L, Schaffer K, Riese M, Burfeind J, Musto K, Feng C, Messing E, Mohile S, Fung C. A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa) Annals of Oncology. 28: v280. DOI: 10.1200/Jco.2017.35.6_Suppl.179 |
0.308 |
|
| 2017 |
Nguyen H, Welty C, Lindquist K, Ngo V, Gilbert E, Bengtsson H, Magi-Galluzzi C, Jean Gilles J, Yao J, Cooperberg M, Messing E, Klein E, Carroll P, Paris P. PD71-05 VALIDATION OF GEMCAP AS A DNA BASED BIOMARKER TO PREDICT PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.3172 |
0.304 |
|
| 2017 |
Yang Y, Yeh C, Slavin S, Luo J, Chou F, Wang K, Truong M, Chang C, Messing EM, Yeh S. MP87-13 ESTROGEN RECEPTOR α IN CANCER ASSOCIATED FIBROBLASTS SUPPRESSES PROSTATE CANCER INVASION VIA REDUCING CCL5, IL6 AND MACROPHAGE INFILTRATION IN THE TUMOR MICROENVIRONMENT. Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2717 |
0.346 |
|
| 2017 |
Wu C, Silvers C, Messing E, Lee Y. MP65-02 CANCER EXTRACELLULAR VESICLES PROMOTE BLADDER TUMORIGENESIS BY INDUCING CHRONIC ENDOPLASMIC RETICULUM STRESS AND INFLAMMATION: A NOVEL MECHANISM FOR FIELD CANCERIZATION Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1996 |
0.302 |
|
| 2017 |
Truong M, Weinberg E, Hollenberg G, Borch M, Park JH, Gantz J, Feng C, Frye T, Ghazi A, Wu G, Joseph J, Rashid H, Messing E. MP03-11 INSTITUTIONAL LEARNING CURVE ASSOCIATED WITH IMPLEMENTATION OF A MR/US FUSION BIOPSY PROGRAM USING PIRADS VERSION 2: FACTORS THAT INFLUENCE SUCCESS Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.128 |
0.328 |
|
| 2016 |
Doucette C, Grossman CE, Messing E, Joseph J, Zhang H. High Incidence of Pathologic Upgrading and Upstaging in Clinically Unfavorable Intermediate-Risk Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. 96: E244. PMID 27674162 DOI: 10.1016/J.Ijrobp.2016.06.1237 |
0.324 |
|
| 2016 |
Shang Z, Li Y, Hsu I, Zhang M, Tian J, Wen S, Han R, Messing EM, Chang C, Niu Y, Yeh S. Targeting estrogen/estrogen receptor alpha will enhance Bacillus Calmette-Guerin efficacy in bladder cancer. Oncotarget. PMID 27092883 DOI: 10.18632/Oncotarget.8756 |
0.311 |
|
| 2016 |
Silvers CR, Liu YR, Wu CH, Miyamoto H, Messing EM, Lee YF. Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer. Oncotarget. PMID 26981774 DOI: 10.18632/Oncotarget.8024 |
0.372 |
|
| 2016 |
Haas NB, Manola J, Uzzo RG, Flaherty K, Pins M, Messing EM, DiPaola RS. A multivariate analysis of prognostic factors from assure (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma. Journal of Clinical Oncology. 34: 618-618. DOI: 10.1200/Jco.2016.34.2_Suppl.618 |
0.306 |
|
| 2016 |
Blute ML, Kucherov V, Shapiro DD, Rushmer TJ, Shi F, Fuller B, Richards KA, Abel EJ, Jarrard DF, Messing EM, Downs TM. MP13-12 MODERATE CHRONIC KIDNEY DISEASE (EGFR <60 ML/MIN) PREDICTS RECURRENCE AND PROGRESSION IN BLADDER CANCER PATIENTS TREATED WITH TRANSURETHRAL RESECTION Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2493 |
0.307 |
|
| 2016 |
Nelson B, Osinski T, Gentile D, Messing EM, Beckham C. MP83-05 GLYCOLYTIC AND INFLAMMATORY PATHWAY GENES ARE OVEREXPRESSED IN BLADDER CANCER TUMORS Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2187 |
0.325 |
|
| 2015 |
Ramirez D, Gupta A, Canter D, Harrow B, Dobbs RW, Kucherov V, Mueller E, Streeper N, Uhlman MA, Svatek RS, Messing EM, Lotan Y. Microscopic hematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer. Bju International. PMID 26435378 DOI: 10.1111/Bju.13345 |
0.304 |
|
| 2015 |
Gee JR, Saltzstein DR, Messing E, Kim K, Kolesar J, Huang W, Havighurst TC, Harris L, Wollmer BW, Jarrard D, House M, Parnes H, Bailey HH. Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (Ecp). PMID 26313229 DOI: 10.1097/Cej.0000000000000189 |
0.347 |
|
| 2015 |
Shang Z, Li Y, Zhang M, Tian J, Han R, Shyr CR, Messing E, Yeh S, Niu Y, Chang C. Anti-androgen therapy with Hydroxyflutamide or androgen receptor degradation enhancer ASC-J9® enhances BCG efficacy to better suppress bladder cancer progression. Molecular Cancer Therapeutics. PMID 26264279 DOI: 10.1158/1535-7163.Mct-14-1055-T |
0.363 |
|
| 2015 |
Rojas KD, Montero ML, Yao J, Messing E, Fazili A, Joseph J, Ou Y, Rubens DJ, Parker KJ, Davatzikos C, Castaneda B. Methodology to study the three-dimensional spatial distribution of prostate cancer and their dependence on clinical parameters. Journal of Medical Imaging (Bellingham, Wash.). 2: 037502. PMID 26236756 DOI: 10.1117/1.Jmi.2.3.037502 |
0.317 |
|
| 2015 |
Wu C, Silvers C, Guancial E, Hsu J, Messing E, Lee Y. Abstract 5475: Cancer exosome promotes cisplatin resistance In bladder cancer and inhibition of exosome sensitizes bladder cancer cells to cisplatin chemotherapy Cancer Research. 75: 5475-5475. DOI: 10.1158/1538-7445.Am2015-5475 |
0.345 |
|
| 2015 |
Berrondo C, Flax J, Messing EM, Beckham C. Abstract 152: The long non-coding RNA HOTAIR affects exosome-mediated bladder cancer progression Cancer Research. 75: 152-152. DOI: 10.1158/1538-7445.Am2015-152 |
0.347 |
|
| 2015 |
Berrondo C, Flax J, Messing E, Beckham C. MP49-07 CANONICAL WNT PATHWAY TUMOR PROGRESSION IS MEDIATED BY THE LONG NON-CODING RNA HOTAIR IN BLADDER CANCER Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.511 |
0.303 |
|
| 2015 |
Silvers C, Hiroshi M, Wu C, Messing E, Lee Y. MP49-18 IDENTIFICATION OF EXTRACELLULAR VESICLE PERIOSTIN AS A URINARY BIOMARKER OF MUSCLE INVASIVE BLADDER CANCER Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2813 |
0.301 |
|
| 2015 |
Silvers C, Wu C, Yin P, Liu Y, Messing E, Lee Y. MP68-14 EXTRACELLULAR VESICLES AS BIOMARKERS AND DIAGNOSTICS IN BLADDER CANCER Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2476 |
0.309 |
|
| 2015 |
Yeh C, Hsu I, Miyamoto H, Wu X, Chang C, Guancial E, Messing EM, Yeh S. Mp68-13 Estrogen Receptor Alpha Prevents Bladder Cancer Via Inpp4B Inhibited Akt Pathway In Vitro And In Vivo The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2475 |
0.315 |
|
| 2015 |
Berrondo C, Flax J, Messing E, Beckham C. MP68-01 THE LONG NON-CODING RNA HOTAIR MODULATES EXOSOME CONTENT AND FUNCTION IN BLADDER CANCER TUMOR PROGRESSION Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2463 |
0.331 |
|
| 2014 |
Baack Kukreja JE, Scosyrev E, Brasacchio RA, Toy EP, Messing EM, Wu G. Bladder cancer incidence and mortality in patients treated with radiation for uterine cancer. Bju International. 114: 844-51. PMID 26010047 DOI: 10.1111/Bju.12543 |
0.313 |
|
| 2014 |
Yasmin-Karim S, King MR, Messing EM, Lee YF. E-selectin ligand-1 controls circulating prostate cancer cell rolling/adhesion and metastasis. Oncotarget. 5: 12097-110. PMID 25301730 DOI: 10.18632/Oncotarget.2503 |
0.348 |
|
| 2014 |
Hsu I, Yeh CR, Slavin S, Miyamoto H, Netto GJ, Tsai YC, Muyan M, Wu XR, Messing EM, Guancial EA, Yeh S. Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo. Oncotarget. 5: 7917-35. PMID 25277204 DOI: 10.18632/Oncotarget.1421 |
0.338 |
|
| 2014 |
Krabbe LM, Svatek RS, Shariat SF, Messing E, Lotan Y. Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort. Urologic Oncology. 33: 65.e19-25. PMID 25044253 DOI: 10.1200/Jco.2014.32.15_Suppl.4546 |
0.302 |
|
| 2014 |
Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urologic Oncology. 32: 826-32. PMID 24931270 DOI: 10.1016/J.Urolonc.2014.01.020 |
0.3 |
|
| 2014 |
Beckham CJ, Olsen J, Yin PN, Wu CH, Ting HJ, Hagen FK, Scosyrev E, Messing EM, Lee YF. Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression. The Journal of Urology. 192: 583-92. PMID 24530986 DOI: 10.1016/J.Juro.2014.02.035 |
0.341 |
|
| 2014 |
Slavin S, Yeh CR, Da J, Yu S, Miyamoto H, Messing EM, Guancial E, Yeh S. Estrogen receptor α in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3. Carcinogenesis. 35: 1301-9. PMID 24374826 DOI: 10.1093/Carcin/Bgt488 |
0.331 |
|
| 2014 |
Donsky H, Coyle S, Scosyrev E, Messing EM. Sex differences in incidence and mortality of bladder and kidney cancers: national estimates from 49 countries. Urologic Oncology. 32: 40.e23-31. PMID 23831109 DOI: 10.1016/J.Urolonc.2013.04.010 |
0.311 |
|
| 2014 |
Zhang H, Messing EM, Ahmed H, Chen Y. Gleason score upgrade among 10,282 men who underwent surgery as initial treatment in 2010: A population-based study. Journal of Clinical Oncology. 32: 72-72. DOI: 10.1200/Jco.2014.32.4_Suppl.72 |
0.322 |
|
| 2014 |
Kilari D, Iczkowski K, Robin A, Pandya C, Bylow KA, Langenstroer P, Messing EM, Guancial EA, Kim ES. Association between copper transporter receptor 1(CTR1) expression and pathologic outcomes in cisplatin (Pt)-treated bladder cancer (BC) patients. Journal of Clinical Oncology. 32: e15516-e15516. DOI: 10.1200/Jco.2014.32.15_Suppl.E15516 |
0.301 |
|
| 2014 |
Olsen J, Flax JD, Messing EM, Beckham CJ. Abstract 1486: Bladder cancer exosomes contain tumor-associated mRNA and long non-coding RNA and facilitate tumor progression Cancer Research. 74: 1486-1486. DOI: 10.1158/1538-7445.Am2014-1486 |
0.328 |
|
| 2014 |
Yasmin-Karim S, Messing E, Lee Y. MP31-19 E-SELETIN LIGAND-1 CONTROLS CIRCULATING PROSTATE CANCER CELLS’ ROLLING AND ADHESION AND METASTASIS Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.928 |
0.325 |
|
| 2014 |
Yeh C, Slavin S, Da J, Chang C, Messing EM, Miyamoto H, Yeh S. MP52-13 ESTROGEN RECEPTOR α IN CANCER ASSOCIATED FIBROBLASTS SUPPRESSES PROSTATE CANCER INVASION VIA MODULATION OF THROMBOSPONDIN-2 AND MATRIX METALLOPROTEINASE 3 Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1623 |
0.354 |
|
| 2014 |
Yeh C, Hsu I, Slavin S, Chang C, Messing EM, Miyamoto H, Yeh S. MP34-02 ESTROGEN RECEPTOR ALPHA PREVENTS BLADDER CANCER VIA INPP4B/AKT PATHWAY: IN VIVO KNOCKOUT MOUSE EVIDENCE AND HUMAN TISSUE ANALYSIS Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1015 |
0.315 |
|
| 2013 |
Travis LB, Messing EM, Hyrien O, Chen R, Milano MT, Brasacchio RA, Chen Y. PSA-detected prostate cancer in the United States: A population-based study of 70,345 men with AJCC stage T1cN0M0 disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 50. PMID 28137053 DOI: 10.1200/Jco.2013.31.6_Suppl.50 |
0.339 |
|
| 2013 |
Pandya C, Fung C, Sahasrabudhe DM, Brasacchio RA, Messing EM, Sievert L, Mohile SG. Characteristics and outcomes of elderly patients with systemic prostate cancer (PCa) treated with peripheral androgen blockade (PAB). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 226. PMID 28136994 DOI: 10.1200/Jco.2013.31.6_Suppl.226 |
0.309 |
|
| 2013 |
Zhang H, Messing EM, Travis LB, Hyrien O, Chen R, Milano MT, Chen Y. Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men. Frontiers in Oncology. 3: 312. PMID 24392353 DOI: 10.3389/Fonc.2013.00312 |
0.338 |
|
| 2013 |
Dogra VS, Chinni BK, Valluru KS, Joseph JV, Ghazi A, Yao JL, Evans K, Messing EM, Rao NA. Multispectral Photoacoustic Imaging of Prostate Cancer: Preliminary Ex-vivo Results. Journal of Clinical Imaging Science. 3: 41. PMID 24228210 DOI: 10.4103/2156-7514.119139 |
0.308 |
|
| 2013 |
Yang DR, Lin SJ, Ding XF, Miyamoto H, Messing E, Li LQ, Wang N, Chang C. Higher expression of peroxisome proliferator-activated receptor γ or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasion. Urology. 81: 1109.e1-6. PMID 23522297 DOI: 10.1016/J.Urology.2012.12.027 |
0.321 |
|
| 2013 |
Larré S, Catto JW, Cookson MS, Messing EM, Shariat SF, Soloway MS, Svatek RS, Lotan Y, Zlotta AR, Grossman HB. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. European Urology. 63: 1049-58. PMID 23313034 DOI: 10.1016/J.Eururo.2012.12.062 |
0.323 |
|
| 2013 |
Scosyrev E, Tobis S, Donsky H, Wu G, Joseph J, Rashid H, Messing E. Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies. Bju International. 111: E71-7. PMID 23017100 DOI: 10.1111/J.1464-410X.2012.11527.X |
0.305 |
|
| 2013 |
Shyr CR, Chen CC, Hsieh TF, Chang CH, Ma WL, Yeh S, Messing E, Li TH, Li FY, Chang C. The expression and actions of androgen receptor in upper urinary tract urothelial carcinoma (UUTUC) tissues and the primary cultured cells. Endocrine. 43: 191-9. PMID 22851332 DOI: 10.1007/S12020-012-9762-4 |
0.309 |
|
| 2013 |
Beckham C, Silvers C, Olsen J, Yin P, Wu C, Ting H, Hagen F, Scosyrev E, Messing E. Abstract B05: Urothelial carcinoma exosomes contain Del1/EDIL-3 and facilitate bladder cancer progression Cancer Research. 73. DOI: 10.1158/1538-7445.Fbcr13-B05 |
0.391 |
|
| 2013 |
Beckham C, Silvers C, Yin PN, Wu C, Ting H, Messing E, Lee YF. 1130 UROTHELIAL CARCINOMA EXOSOMES PROMOTE CANCER PROGRESSION Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.745 |
0.335 |
|
| 2013 |
Baack Kukreja J, Scosyrev E, Messing E, Wu G. 1284 BLADDER CANCER AS A SECONDARY MALIGNANCY AFTER RADIATION THERAPY FOR PRIMARY UTERINE CANCER Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2638 |
0.318 |
|
| 2013 |
Byler T, Wood R, Messing E, Shapiro O, Bratslavsky G, Reeder J. 598 VALPROIC ACID REDUCES TUMOR GROWTH IN A MOUSE MODEL OF SUPERFICIAL BLADDER CANCER Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1994 |
0.32 |
|
| 2012 |
Byler TK, Leocadio D, Shapiro O, Bratslavsky G, Stodgell CJ, Wood RW, Messing EM, Reeder JE. Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression. Bmc Urology. 12: 21. PMID 22898175 DOI: 10.1186/1471-2490-12-21 |
0.348 |
|
| 2012 |
Scosyrev E, Wu G, Mohile S, Messing EM. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer. 118: 5768-76. PMID 22847578 DOI: 10.1002/Cncr.27503 |
0.324 |
|
| 2012 |
Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, et al. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prevention Research (Philadelphia, Pa.). 5: 621-30. PMID 22293631 DOI: 10.1158/1940-6207.Capr-11-0455 |
0.313 |
|
| 2012 |
Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ, Yeh S. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. Bju International. 109: 1716-26. PMID 22221549 DOI: 10.1016/J.Juro.2012.02.453 |
0.306 |
|
| 2012 |
Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer. 118: 3062-70. PMID 22006014 DOI: 10.1002/Cncr.26392 |
0.302 |
|
| 2012 |
Scosyrev E, Messing EM, van Wijngaarden E, Peterson DR, Sahasrabudhe D, Golijanin D, Fisher SG. Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer. 118: 72-81. PMID 21720989 DOI: 10.1002/Cncr.26238 |
0.313 |
|
| 2012 |
Scosyrev E, Messing J, Noyes K, Veazie P, Messing E. Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview. Urologic Oncology. 30: 126-32. PMID 20363162 DOI: 10.1016/J.Urolonc.2009.11.005 |
0.307 |
|
| 2012 |
Yasmin-Karim S, Ting H, King M, Messing E, Lee Y. 476 CAPTURE AND ANALYSIS OF PROSTATE CANCER STEM CELLS USING A MICROCIRCULATORY CHANNEL Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.545 |
0.309 |
|
| 2012 |
Baack Kukreja J, Scosyrev E, Messing E, Wu G. 1281 INCIDENCE OF BLADDER CANCER AS A SECONDARY MALIGNANCY IN PATIENTS TREATED WITH RADIATION FOR CERVICAL CANCER Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1613 |
0.323 |
|
| 2012 |
Yeh C, Chen M, Chang H, Vitkus S, Wen X, Bhowmick N, Wolfe A, Messing EM, Yeh S. 1583 LOSS OF EPITHELIAL OESTROGEN RECEPTOR α INHIBITS OESTROGEN-STIMULATED PROSTATE PROLIFERATION AND SQUAMOUS METAPLASIA VIA IN VIVO TISSUE SELECTIVE KNOCKOUT MODELS Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1355 |
0.323 |
|
| 2011 |
Scosyrev E, Wu G, Golijanin D, Messing E. Non-bladder cancer mortality in patients with urothelial cancer of the bladder. Urologic Oncology. 31: 656-63. PMID 21550827 DOI: 10.1016/J.Urolonc.2011.03.005 |
0.327 |
|
| 2011 |
Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, de Vere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen CM, Crawford ED, Thompson IM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). Bju International. 108: 693-9. PMID 21105991 DOI: 10.1111/J.1464-410X.2010.09900.X |
0.3 |
|
| 2011 |
Mir C, Shariat SF, van der Kwast TH, Ashfaq R, Lotan Y, Evans A, Skeldon S, Hanna S, Vajpeyi R, Kuk C, Alkhateeb S, Morote J, van Rhijn BW, Bostrom P, Yao J, ... ... Messing E, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. Bju International. 108: 24-30. PMID 21070579 DOI: 10.1111/J.1464-410X.2010.09834.X |
0.326 |
|
| 2011 |
He X, Wang J, Messing EM, Wu G. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness. Oncogene. 30: 535-47. PMID 20871634 DOI: 10.1038/Onc.2010.427 |
0.765 |
|
| 2011 |
Purnell JQ, Palesh OG, Heckler CE, Adams MJ, Chin N, Mohile S, Peppone LJ, Atkins JN, Moore DF, Spiegel D, Messing E, Morrow GR. Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 19: 899-907. PMID 20414685 DOI: 10.1007/S00520-010-0880-3 |
0.328 |
|
| 2011 |
Scosyrev E, Wu G, Golijanin D, Messing E. 1900 NON-BLADDER CANCER MORTALITY IN PATIENTS WITH UROTHELIAL CANCER OF THE BLADDER Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2024 |
0.325 |
|
| 2010 |
Kohli M, Rothberg PG, Feng C, Messing E, Joseph J, Rao SS, Hendershot A, Sahsrabudhe D. Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Cancer Biomarkers : Section a of Disease Markers. 7: 101-8. PMID 21178268 DOI: 10.3233/Cbm-2010-0152 |
0.309 |
|
| 2010 |
Scosyrev E, Trivedi D, Messing E. Female bladder cancer: incidence, treatment, and outcome. Current Opinion in Urology. 20: 404-8. PMID 20592613 DOI: 10.1097/Mou.0B013E32833C7A9B |
0.307 |
|
| 2010 |
Lerner SP, Grossman HB, Messing EM, Kibel AS, Stephenson A, Gee JR, O'Donnell MA, Reid RD, Kamat AM, Parnes HL, House MG. BCAN Think Tank session 3: Prevention of bladder cancer. Urologic Oncology. 28: 338-42. PMID 20439034 DOI: 10.1016/J.Urolonc.2009.06.018 |
0.324 |
|
| 2010 |
Robinson VL, Porter M, Messing E, Fradet Y, Kamat AM, Lotan Y. BCAN Think Tank session 2: Molecular detection of bladder cancer: the path to progress. Urologic Oncology. 28: 334-7. PMID 20439033 DOI: 10.1016/J.Urolonc.2009.07.026 |
0.323 |
|
| 2010 |
Karim-Yasmin S, Hsu J, Ting H, Messing E, Lee Y. 1196 CIRCULATING ROLLING PROSTATE CANCER CELLS POTENTIATE METASTASIS: A MICRO-CHANNEL MODEL Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.697 |
0.323 |
|
| 2009 |
Trivedi D, Messing EM. Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria. Bmc Urology. 9: 13. PMID 19744318 DOI: 10.1186/1471-2490-9-13 |
0.324 |
|
| 2009 |
Madeb R, Golijanin D, Noyes K, Fisher S, Stephenson JJ, Long SR, Knopf J, Lyman GH, Messing EM. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer. 115: 2660-70. PMID 19455607 DOI: 10.1002/Cncr.24311 |
0.326 |
|
| 2009 |
Messing EM, Madeb R, Feng C, Stephenson L, Gilchrist KW, Young T, Gee J. Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2443-9. PMID 19332735 DOI: 10.1200/Jco.2008.16.5951 |
0.306 |
|
| 2009 |
Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial Journal of Urology. 181: 956-962. PMID 19167731 DOI: 10.1016/J.Juro.2008.11.032 |
0.323 |
|
| 2009 |
Gee JR, Jarrard DF, Bruskewitz RC, Moon TD, Hedican SP, Leverson GE, Nakada SY, Messing EM. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin. Bju International. 103: 736-9. PMID 19007364 DOI: 10.1111/J.1464-410X.2008.08123.X |
0.325 |
|
| 2009 |
Golijanin DJ, Singer EA, Chen Y, Manola J, Palapattu GS, Messing EM. INFLUENCE OF SERUM TESTOSTERONE LEVEL AND BODY MASS INDEX ON SURVIVAL IN MEN TREATED WITH IMMEDIATE VERSUS DEFERRED ANDROGEN DEPRIVATION FOR NODE-POSITIVE PROSTATE CANCER AFTER PROSTATECTOMY AND PELVIC LYMPHADENECTOMY Journal of Urology. 181: 270-270. DOI: 10.1016/S0022-5347(09)60769-2 |
0.306 |
|
| 2008 |
Sahasrabudhe DM, Messing E, Schoen SR, Feng C, Joseph J, Constantino A, VidyaRao S, Kohli M. A cross-sectional study of angiopoietin-1 (Ang-1) in early and advanced prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5137. PMID 27948214 DOI: 10.1200/Jco.2008.26.15_Suppl.5137 |
0.367 |
|
| 2008 |
Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S, Chang C. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 105: 12182-7. PMID 18723679 DOI: 10.1073/Pnas.0804700105 |
0.364 |
|
| 2008 |
Johnson AM, O'Connell MJ, Messing EM, Reeder JE. Decreased bladder cancer growth in parous mice. Urology. 72: 470-3. PMID 18533230 DOI: 10.1016/J.Urology.2008.04.028 |
0.322 |
|
| 2008 |
Johnson AM, O'Connell MJ, Miyamoto H, Huang J, Yao JL, Messing EM, Reeder JE. Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. Bmc Urology. 8: 7. PMID 18433501 DOI: 10.1186/1471-2490-8-7 |
0.332 |
|
| 2008 |
Messing EM. Why should we increase public awareness of bladder cancer, and how can we do it? Nature Clinical Practice. Urology. 5: 117. PMID 18322472 DOI: 10.1038/Ncpuro1061 |
0.309 |
|
| 2008 |
Zhang M, Nigwekar P, Castaneda B, Hoyt K, Joseph JV, di Sant'Agnese A, Messing EM, Strang JG, Rubens DJ, Parker KJ. Quantitative characterization of viscoelastic properties of human prostate correlated with histology. Ultrasound in Medicine & Biology. 34: 1033-42. PMID 18258350 DOI: 10.1016/J.Ultrasmedbio.2007.11.024 |
0.326 |
|
| 2008 |
Singer EA, Golijanin DJ, Miyamoto H, Messing EM. Androgen deprivation therapy for prostate cancer. Expert Opinion On Pharmacotherapy. 9: 211-28. PMID 18201145 DOI: 10.1517/14656566.9.2.211 |
0.33 |
|
| 2008 |
Messing EM, Scosyrev E, Feng C, Noyes K. GENDER AND RACIAL DIFFERENCES IN BLADDER CANCER MORTALITY: HOW MUCH OF A ROLE DO TUMOR FACTORS AT PRESENTATION PLAY? Journal of Urology. 179: 580-581. DOI: 10.1016/S0022-5347(08)61703-6 |
0.315 |
|
| 2008 |
Yeh S, Ni J, Messing EM, Chemler S, James NS, Chen M, Hsu I. LOW TOXICITY AND HIGH ANTICANCER EFFICACY OF A NOVEL VITAMIN E ETHER ANALOG IN PRECLINICAL PROSTATE CANCER ANIMAL MODELS Journal of Urology. 179: 225-225. DOI: 10.1016/S0022-5347(08)60649-7 |
0.3 |
|
| 2008 |
Niu Y, Han R, Yeh S, Messing EM, Chang C. THE PROSTATIC EPITHELIAL SPECIFIC ANDROGEN RECEPTOR KNOCKOUT TRAMP MICE: AN ANIMAL MODEL FOR ANDROGEN INDEPENDENT PROSTATIC TUMOR Journal of Urology. 179: 188-188. DOI: 10.1016/S0022-5347(08)60546-7 |
0.305 |
|
| 2007 |
Messing E. Markers of detection. Urologic Oncology. 25: 344-7. PMID 17628306 DOI: 10.1016/J.Urolonc.2007.05.012 |
0.318 |
|
| 2007 |
Madeb R, Golijanin D, Knopf J, Messing EM. Current state of screening for bladder cancer. Expert Review of Anticancer Therapy. 7: 981-7. PMID 17627458 DOI: 10.1586/14737140.7.7.981 |
0.343 |
|
| 2007 |
Messing EM. Re: Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. European Urology. 51: 1140. PMID 17415910 DOI: 10.1016/J.Eururo.2007.01.056 |
0.312 |
|
| 2007 |
Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C. Promotion of bladder cancer development and progression by androgen receptor signals. Journal of the National Cancer Institute. 99: 558-68. PMID 17406000 DOI: 10.1093/Jnci/Djk113 |
0.357 |
|
| 2007 |
Messing EM. Node positive renal cell cancer. Who can be helped? European Urology. 51: 1477-8. PMID 17240037 DOI: 10.1016/J.Eururo.2007.01.034 |
0.356 |
|
| 2007 |
Messing EM, Golijanin D, Palapattu GS, Feng C, Young T, Gilchrist KW, Bram L, Stephenson L, Gee J, Madeb RR. 1651: Non-Bladder Cancer Causes of Death Among Patients with Newly Diagnosed Bladder Cancer: A Competing Risks Analysis in a Population-Based Study Journal of Urology. 177: 547-548. DOI: 10.1016/S0022-5347(18)31839-1 |
0.321 |
|
| 2007 |
He X, Messing EM, Wu G. 444: The Von Hippel-Lindau Tumor Suppressor Promotes TNF-A-Induced Renal Carcinoma Cell Apoptosis by Binding Casein Kinase 2A and Impairing NF-KB Survival Signaling Journal of Urology. 177: 149-149. DOI: 10.1016/S0022-5347(18)30697-9 |
0.755 |
|
| 2006 |
Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. Jama. 296: 2329-35. PMID 17105795 DOI: 10.1001/Jama.296.19.2329 |
0.363 |
|
| 2006 |
Golijanin DJ, Kakiashvili D, Madeb RR, Messing EM, Lerner SP. Chemoprevention of bladder cancer. World Journal of Urology. 24: 445-72. PMID 17048030 DOI: 10.1007/S00345-006-0123-X |
0.326 |
|
| 2006 |
Boczko J, Messing E, Dogra V. Transrectal Sonography in Prostate Evaluation Radiologic Clinics of North America. 44: 679-687. PMID 17030220 DOI: 10.1016/J.Rcl.2006.07.001 |
0.302 |
|
| 2006 |
Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. The Journal of Urology. 176: 500-4. PMID 16813878 DOI: 10.1016/J.Juro.2006.03.061 |
0.314 |
|
| 2006 |
Wood RW, Baggs RB, Schwarz EM, Messing EM. Initial observations of reduced uroflow in transgenic adenocarcinoma of murine prostate. Urology. 67: 1324-8. PMID 16765198 DOI: 10.1016/J.Urology.2005.12.019 |
0.325 |
|
| 2006 |
Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. The Lancet. Oncology. 7: 472-9. PMID 16750497 DOI: 10.1016/S1470-2045(06)70700-8 |
0.34 |
|
| 2006 |
Palapattu GS, Messing EM. Do prostate cancer patients at risk of pelvic lymph-node metastasis benefit from pelvic radiation? Nature Clinical Practice. Urology. 3: 258-9. PMID 16691238 DOI: 10.1038/Ncpuro0463 |
0.306 |
|
| 2006 |
Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. Jama. 295: 299-305. PMID 16418465 DOI: 10.1001/Jama.295.3.299 |
0.346 |
|
| 2006 |
Ni J, Wen X, Yao JL, Yin Y, Zhang M, Xie S, Chen M, Simons B, Disant'agnese A, Messing EM, Yeh S. 823: Tocopherol Associated Protein Suppresses Prostate Cancer Cell Growth by Inhibition of the PI3 Kinase Pathway Journal of Urology. 175: 265-266. DOI: 10.1016/S0022-5347(18)33059-3 |
0.354 |
|
| 2005 |
Habuchi T, Marberger M, Droller MJ, Hemstreet GP, Grossman HB, Schalken JA, Schmitz-Dräger BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y, Lokeshwar VB. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology. 66: 64-74. PMID 16399416 DOI: 10.1016/J.Urology.2005.08.065 |
0.36 |
|
| 2005 |
Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 66: 35-63. PMID 16399415 DOI: 10.1016/J.Urology.2005.08.064 |
0.356 |
|
| 2005 |
Ni J, Wen X, Yao J, Chang HC, Yin Y, Zhang M, Xie S, Chen M, Simons B, Chang P, di Sant'Agnese A, Messing EM, Yeh S. Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway. Cancer Research. 65: 9807-16. PMID 16267002 DOI: 10.1158/0008-5472.Can-05-1334 |
0.377 |
|
| 2005 |
Miyamoto H, Messing EM, Chang C. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer? Nature Clinical Practice. Oncology. 2: 236-7. PMID 16264955 DOI: 10.1038/Ncponc0168 |
0.307 |
|
| 2005 |
Taylor LS, Rubens DJ, Porter BC, Wu Z, Baggs RB, di Sant'Agnese PA, Nadasdy G, Pasternack D, Messing EM, Nigwekar P, Parker KJ. Prostate cancer: three-dimensional sonoelastography for in vitro detection. Radiology. 237: 981-5. PMID 16251396 DOI: 10.1148/Radiol.2373041573 |
0.327 |
|
| 2005 |
Messing EM, Teot L, Korman H, Underhill E, Barker E, Stork B, Qian J, Bostwick DG. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. The Journal of Urology. 174: 1238-41. PMID 16145377 DOI: 10.1097/01.Ju.0000173918.84006.4D |
0.332 |
|
| 2005 |
Miyamoto H, Altuwaijri S, Cai Y, Messing EM, Chang C. Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Molecular Carcinogenesis. 44: 1-10. PMID 16044418 DOI: 10.1002/Mc.20121 |
0.359 |
|
| 2005 |
Li Z, Wang D, Messing EM, Wu G. VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha. Embo Reports. 6: 373-8. PMID 15776016 DOI: 10.1038/Sj.Embor.7400377 |
0.736 |
|
| 2005 |
Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y. Detection of bladder cancer using a point-of-care proteomic assay. Jama. 293: 810-6. PMID 15713770 DOI: 10.1001/Jama.293.7.810 |
0.322 |
|
| 2005 |
Wang D, Li Z, Messing EM, Wu G. The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with MET and enhances the hepatocyte growth factor-induced Erk-Elk-1-serum response element pathway. The Journal of Biological Chemistry. 280: 16393-401. PMID 15713673 DOI: 10.1074/Jbc.M413897200 |
0.752 |
|
| 2005 |
Thompson IM, Tangen C, Miller GJ, Lucia MS, Troyer DA, Paradelo J, Chin JL, Messing EM, Canby-Hagino ED, Forman J, Crawford ED. 1665: Adjuvant Radiotherapy for Pathologic T3 Prostate Cancer: Results of a Randomized, Prospective Clinical Trial with Metastasis-Free Survival Endpoint Journal of Urology. 173: 451-452. DOI: 10.1016/S0022-5347(18)35787-2 |
0.32 |
|
| 2005 |
Wu G, Schoen SR, Wang D, He X, DiMaggio MA, Messing EM. 646: RAS Association Domain Family (RASSF) Expression in Normal Human Tissues and Cancer Cell Lines Journal of Urology. 173: 176-176. DOI: 10.1016/S0022-5347(18)34886-9 |
0.76 |
|
| 2005 |
Wang D, Yao JL, Messing EM, Schoen SR, He X, DiMaggio MA, Bourne P, Yang XJ, di Sant'Agnese PA, Wu G. 625: Bert-Hogg-Dubé (BHD) Tumor Suppressor Expression in Sporadic Renal Cell Carcinomas Journal of Urology. 173: 170-171. DOI: 10.1016/S0022-5347(18)34865-1 |
0.761 |
|
| 2005 |
Swanson G, Thompson I, Tangen C, Miller G, Lucia M, Troyer D, Paradelo J, Chin J, Messing E, Canby-Higano E, Forman J, Crawford D. Phase III Randomized Study of Adjuvant Radiation Therapy versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG 8794) International Journal of Radiation Oncology*Biology*Physics. 63: S1. DOI: 10.1016/J.Ijrobp.2005.07.007 |
0.315 |
|
| 2004 |
Messing EM, Manola J, Sarosdy M, Wilding G, Crawford D, Kiernan M, Trump D. Immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: At 10 years results of EST3886. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4570. PMID 28015974 DOI: 10.1200/Jco.2004.22.14_Suppl.4570 |
0.333 |
|
| 2004 |
Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. The Prostate. 61: 332-53. PMID 15389811 DOI: 10.1002/Pros.20115 |
0.347 |
|
| 2004 |
Rashid HH, Cos LR, Weinberg E, Messing EM. Testicular microlithiasis: a review and its association with testicular cancer. Urologic Oncology. 22: 285-9. PMID 15283884 DOI: 10.1016/S1078-1439(03)00177-7 |
0.359 |
|
| 2004 |
Miyamoto H, Messing EM. Early versus late hormonal therapy for prostate cancer. Current Urology Reports. 5: 188-96. PMID 15161567 DOI: 10.1007/S11918-004-0003-Z |
0.33 |
|
| 2004 |
Madeb R, Messing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urologic Oncology. 22: 86-92. PMID 15082003 DOI: 10.1016/S1078-1439(03)00139-X |
0.316 |
|
| 2004 |
Wright KO, Messing EM, Reeder JE. DBCCR1 mediates death in cultured bladder tumor cells. Oncogene. 23: 82-90. PMID 14712213 DOI: 10.1038/Sj.Onc.1206642 |
0.322 |
|
| 2004 |
Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, Messing E, Okunieff P. Is there a favorable subset of patients with prostate cancer who develop oligometastases? International Journal of Radiation Oncology, Biology, Physics. 58: 3-10. PMID 14697414 DOI: 10.1016/S0360-3016(03)01442-1 |
0.301 |
|
| 2004 |
Wang D, Li Z, Schoen SR, Messing EM, Wu G. A novel MET-interacting protein shares high sequence similarity with RanBPM, but fails to stimulate MET-induced Ras/Erk signaling. Biochemical and Biophysical Research Communications. 313: 320-6. PMID 14684163 DOI: 10.1016/J.Bbrc.2003.11.124 |
0.75 |
|
| 2004 |
Messing EM, Manola J, Yao J, Kiernan M, Crawford ED, Wilding G, di'SantAgnese PA. 1455: Immediate VS Delayed Hormonal Therapy (HT) in Patients with Nodal Positive (N+) Prostate Cancer Who Had Undergone Radical Prostatectomy (RP) + Pelvic Lymphadenectomy (LND): Results of Central Pathology Review (CPR) Journal of Urology. 171: 383-383. DOI: 10.1016/S0022-5347(18)38680-4 |
0.312 |
|
| 2004 |
Wu G, Li Z, Wang D, Messing EM. 777: The Von Hippel-Lindau Protein-Interacting Deubiquitinating Enzyme 2 Deubiquitinates and Stabilizes Hypoxia-Inducible Factor-1α Journal of Urology. 171: 206-206. DOI: 10.1016/S0022-5347(18)38026-1 |
0.732 |
|
| 2003 |
Messing EM, Thompson I. Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy. The Urologic Clinics of North America. 30: 687-702, viii. PMID 14680308 DOI: 10.1016/S0094-0143(03)00050-8 |
0.32 |
|
| 2003 |
Messing E. The timing of hormone therapy for men with asymptomatic advanced prostate cancer. Urologic Oncology. 21: 245-54. PMID 12954493 DOI: 10.1016/S1078-1439(03)00016-4 |
0.307 |
|
| 2003 |
Reeder JE, Sowden MP, Messing EM, Klover P, Villa-Moruzzi E, Ludlow JW. Inducible expression of catalytically active type 1 serine/threonine protein phosphatase in a human carcinoma cell line. Cancer Cell International. 3: 12. PMID 12914669 DOI: 10.1186/1475-2867-3-12 |
0.327 |
|
| 2003 |
Na X, Duan HO, Messing EM, Schoen SR, Ryan CK, di Sant'Agnese PA, Golemis EA, Wu G. Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. The Embo Journal. 22: 4249-59. PMID 12912922 DOI: 10.1093/Emboj/Cdg410 |
0.747 |
|
| 2003 |
Na X, Wu G, Ryan CK, Schoen SR, di'Santagnese PA, Messing EM. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. The Journal of Urology. 170: 588-92. PMID 12853836 DOI: 10.1097/01.Ju.0000074870.54671.98 |
0.743 |
|
| 2003 |
Borhan A, Reeder JE, O'Connell MJ, Wright KO, Wheeless LL, di Sant'Agnese PA, McNally ML, Messing EM. Grade progression and regression in recurrent urothelial cancer. The Journal of Urology. 169: 2106-9. PMID 12771728 DOI: 10.1097/01.Ju.0000067160.09881.45 |
0.342 |
|
| 2003 |
Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. The Embo Journal. 22: 1857-67. PMID 12682018 DOI: 10.1093/Emboj/Cdg173 |
0.754 |
|
| 2002 |
Wright KO, Messing EM, Reeder JE. Increased expression of the acid sphingomyelinase-like protein ASML3a in bladder tumors. The Journal of Urology. 168: 2645-9. PMID 12442002 DOI: 10.1016/S0022-5347(05)64236-X |
0.331 |
|
| 2002 |
Wang D, Li Z, Messing EM, Wu G. Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM. The Journal of Biological Chemistry. 277: 36216-22. PMID 12147692 DOI: 10.1074/Jbc.M205111200 |
0.759 |
|
| 2002 |
Sessions AE, Messing EM. Timing hormonal therapy in prostate cancer. The Urologic Clinics of North America. 29: 223-7, xi. PMID 12109348 DOI: 10.1016/S0094-0143(02)00007-1 |
0.324 |
|
| 2002 |
Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Biochemical and Biophysical Research Communications. 294: 700-9. PMID 12056827 DOI: 10.1016/S0006-291X(02)00534-X |
0.755 |
|
| 2002 |
Zhang Y, Ni J, Messing EM, Chang E, Yang CR, Yeh S. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 99: 7408-13. PMID 12032296 DOI: 10.1073/Pnas.102014399 |
0.357 |
|
| 2002 |
Fisher TL, Nocera M, Willis RA, Turner MJ, Abdul Alim CS, Brown DM, Bourne PA, di Sant'Agnese PA, Messing EM, Lord EM, Frelinger JG. Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors. The Prostate. 51: 153-65. PMID 11967950 DOI: 10.1002/Pros.10071 |
0.346 |
|
| 2002 |
Li Z, Na X, Wang D, Schoen SR, Messing EM, Wu G. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. The Journal of Biological Chemistry. 277: 4656-62. PMID 11739384 DOI: 10.1074/Jbc.M108269200 |
0.763 |
|
| 2002 |
Singh D, Yi W, Brasacchio R, Muhs A, Smudzin T, Williams J, Messing E, Okunieff P. Is there a favorable subset of patients with metastatic prostate cancer who have oligometastases International Journal of Radiation Oncology*Biology*Physics. 54: 193. DOI: 10.1016/S0360-3016(02)03390-4 |
0.349 |
|
| 2001 |
Brawer MK, Stamey TA, Fowler J, Droller M, Messing E, Fair WR. Perspectives on prostate cancer diagnosis and treatment: a roundtable. Urology. 58: 135-40. PMID 11489681 DOI: 10.1016/S0090-4295(01)01178-5 |
0.332 |
|
| 2000 |
Eichel L, Messing E. The timing of hormonal treatment for prostate cancer. Current Opinion in Urology. 10: 403-407. PMID 11005443 DOI: 10.1097/00042307-200009000-00007 |
0.334 |
|
| 2000 |
Jung I, Messing E. Molecular mechanisms and pathways in bladder cancer development and progression Cancer Control. 7: 325-334. PMID 10895126 DOI: 10.1177/107327480000700401 |
0.351 |
|
| 2000 |
Swanson GP, Messing EM, Manola J. Early hormonal therapy in prostate cancer [1] (multiple letters) The New England Journal of Medicine. 342: 1215-1216. PMID 10777375 DOI: 10.1056/Nejm200004203421613 |
0.325 |
|
| 1999 |
Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. The New England Journal of Medicine. 341: 1781-8. PMID 10588962 DOI: 10.1056/Nejm199912093412401 |
0.337 |
|
| 1999 |
Messing EM, Love RR, Tutsch KD, Verma AK, Douglas J, Pomplun M, Simsiman R, Wilding G. Low-dose difluoromethylornithine and polyamine levels in human prostate tissue Journal of the National Cancer Institute. 91: 1416-1417. PMID 10451448 DOI: 10.1093/Jnci/91.16.1416 |
0.334 |
|
| 1999 |
Messing E, Manola J, Wilding G, Sarosdy M, Crawford D, Trump D. Immediate Hormonal Therapy Vs. Observation For Node Positive Prostate Cancer Following Radical Prostatectomy And Pelvic Lymphadenectomy: A Randomized Phase Iii Eastern Cooperative Oncology Group/Inter Group Trial The Journal of Urology. 175. DOI: 10.1097/00005392-199904010-00701 |
0.304 |
|
| 1998 |
Miyamoto H, Yeh S, Lardy H, Messing E, Chang C. δ5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells Proceedings of the National Academy of Sciences of the United States of America. 95: 11083-11088. PMID 9736693 DOI: 10.1073/Pnas.95.19.11083 |
0.344 |
|
| 1997 |
Foresman WH, Messing EM. Bladder cancer: natural history, tumor markers, and early detection strategies. Seminars in Surgical Oncology. 13: 299-306. PMID 9259085 DOI: 10.1002/(Sici)1098-2388(199709/10)13:5<299::Aid-Ssu3>3.0.Co;2-8 |
0.331 |
|
| 1996 |
White RWd, Deitch AD, Tesluk H, Blumensteinj B, Lowe BA, Sagalowsky AI, Smith JA, Schellhammer PF, Stanisic TH, Grossman HB, Messing E, Crissman JD, Crawford ED. Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study. Urologic Oncology-Seminars and Original Investigations. 2: 27-34. PMID 21224132 DOI: 10.1016/1078-1439(96)00031-2 |
0.312 |
|
| 1996 |
Wu SQ, Hafez GR, Xing W, Newton M, Chen XR, Messing E. The correlation between the loss of chromosome 14q with histologic tumor grade, pathologic stage, and outcome of patients with nonpapillary renal cell carcinoma. Cancer. 77: 1154-60. PMID 8635138 DOI: 10.1002/(SICI)1097-0142(19960315)77:6<1154::AID-CNCR23>3.0.CO;2-# |
0.302 |
|
| 1996 |
Soloway MS, Briggman JV, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing E, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL. Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract Following Surgical Treatment Journal of Urology. 156: 363-367. DOI: 10.1016/S0022-5347(01)65851-8 |
0.323 |
|
| 1995 |
Lamm DL, Blumenstein BA, David Crawford E, Crissman JD, Lowe BA, Smith JA, Sarosdy MF, Schellhammer PF, Sagalowsky AI, Messing EM, Loehrer P, Barton Grossman H. Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urologic Oncology. 1: 119-26. PMID 21224104 DOI: 10.1016/1078-1439(95)00041-F |
0.304 |
|
| 1995 |
Jønler M, Ritter MA, Brinkmann R, Messing EM, Rhodes PR, Bruskewitz RC. Sequelae of definitive radiation therapy for prostate cancer localized to the pelvis. Urology. 44: 876-82. PMID 7985316 DOI: 10.1016/S0090-4295(94)80174-6 |
0.317 |
|
| 1995 |
Messing EM, Young TB, Hunt VB, Newton MA, Bram LL, Vaillancourt A, Hisgen WJ, Greenberg EB, Kuglitsch ME, Wegenke JD. Hematuria Home Screening: Repeat Testing Results The Journal of Urology. 154: 57-61. PMID 7776456 DOI: 10.1016/S0022-5347(01)67224-0 |
0.326 |
|
| 1995 |
Glazier DB, Bahnson RR, McLeod DG, von Roemeling RW, Messing EM, Ernstoff MS. Intravesical Recombinant Tumor Necrosis Factor in the Treatment of Superficial Bladder Cancer: An Eastern Cooperative Oncology Group Study Journal of Urology. 154: 66-68. DOI: 10.1016/S0022-5347(01)67228-8 |
0.334 |
|
| 1994 |
Messing EM, Murphy-Brooks N. Recovery of epidermal growth factor in voided urine of patients with bladder cancer. Urology. 44: 502-6. PMID 7941190 DOI: 10.1016/S0090-4295(94)80047-2 |
0.33 |
|
| 1994 |
Jonler M, Messing EM. Detection, diagnosis, and natural history of bladder cancer Current Opinion in Urology. 4: 269-274. DOI: 10.1097/00042307-199409000-00008 |
0.301 |
|
| 1993 |
Phillips E, Messing EM. Role of lymphadenectomy in the treatment of renal cell carcinoma. Urology. 41: 9-15. PMID 8420090 DOI: 10.1016/0090-4295(93)90234-2 |
0.304 |
|
| 1993 |
Messing EM. Growth factors and bladder cancer: clinical implications of the interactions between growth factors and their urothelial receptors. Seminars in Surgical Oncology. 8: 285-92. PMID 1462099 DOI: 10.1002/Ssu.2980080507 |
0.304 |
|
| 1993 |
Messing EM, Reznikoff CA. Epidermal growth factor and its receptor: markers of--and targets for--chemoprevention of bladder cancer. Journal of Cellular Biochemistry. Supplement. 56-62. PMID 1305689 DOI: 10.1002/Jcb.240501312 |
0.312 |
|
| 1993 |
Loprinzi CL, Messing EM. A prospective clinical trial of difluoromethylornithine (DFMO) in patients with resected superficial bladder cancer. Journal of Cellular Biochemistry. Supplement. 153-5. PMID 1305680 DOI: 10.1002/Jcb.240501329 |
0.359 |
|
| 1992 |
Messing EM, Young TB, Hunt VB, Roecker EB, Vaillancourt AM, Hisgen WJ, Greenberg EB, Kuglitsch ME, Wegenke JD. Home screening for hematuria: results of a multiclinic study. The Journal of Urology. 148: 289-92. PMID 1635120 DOI: 10.1016/S0022-5347(17)36575-8 |
0.304 |
|
| 1992 |
Briggs NC, Young TB, Gilchrist KW, Vaillancourt AM, Messing EM. Age as a predictor of an aggressive clinical course for superficial bladder cancer in men. Cancer. 69: 1445-51. PMID 1540882 DOI: 10.1002/1097-0142(19920315)69:6<1445::Aid-Cncr2820690623>3.0.Co;2-S |
0.304 |
|
| 1992 |
Ritter MA, Messing EM, Shanahan TG, Potts S, Choppell RJ, Kinsella TJ. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer Journal of Clinical Oncology. 10: 1208-1217. PMID 1378886 DOI: 10.1200/Jco.1992.10.8.1208 |
0.333 |
|
| 1991 |
Huland E, Huland H, Meier T, Baricordi O, Fradet Y, Grossman HB, Hodges GM, Messing EM, Schmitz-Draeger BJ. Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder Journal of Urology. 146: 1631-1636. PMID 1719252 DOI: 10.1016/S0022-5347(17)38202-2 |
0.343 |
|
| 1991 |
Huland E, Huland H, Meier T, Baricordi O, Fradet Y, Grossman HB, Hodges GM, Messing EM, Schmitz-Draeger BJ. The significance of immune cytological diagnostics for bladder carcinoma Oncology Research and Treatment. 14: 385-390. DOI: 10.1159/000217013 |
0.316 |
|
| 1990 |
Dreicer R, Messing EM, Loehrer PJ, Trump DL. Perioperative methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for poor risk transitional cell carcinoma of the bladder: an Eastern Cooperative Oncology Group pilot study. The Journal of Urology. 144: 1123-6; discussion 1. PMID 2231884 DOI: 10.1016/S0022-5347(17)39673-8 |
0.322 |
|
| 1990 |
Messing EM, Vaillancourt A. Hematuria screening for bladder cancer Journal of Occupational Medicine. 32: 838-845. PMID 2074507 DOI: 10.1097/00043764-199009000-00016 |
0.338 |
|
| 1989 |
Messing EM, Young TB, Hunt VB, Wehbie JM, Rust P. Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age. Cancer. 64: 2361-7. PMID 2804928 DOI: 10.1002/1097-0142(19891201)64:11<2361::Aid-Cncr2820641128>3.0.Co;2-4 |
0.309 |
|
| 1989 |
Goldrath DE, Messing EM. Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy. The Journal of Urology. 142: 1082-4. PMID 2477560 DOI: 10.1016/S0022-5347(17)38998-X |
0.321 |
|
| 1989 |
Trump DL, Havlin KH, Messing EM, Cummings KB, Lange PH, Jordan VC. High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 1093-8. PMID 2474059 DOI: 10.1200/Jco.1989.7.8.1093 |
0.314 |
|
| 1987 |
Messing EM, Young TB, Hunt VB, Emoto SE, Wehbie JM. The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks. The Journal of Urology. 137: 919-22. PMID 2437335 DOI: 10.1016/S0022-5347(17)44294-7 |
0.302 |
|
| 1981 |
Messing E, deKernion JB. Adjuvant therapy for genitourinary cancer. Surgical Clinics of North America. 61: 1331-1346. PMID 7198295 DOI: 10.1016/S0039-6109(16)42588-0 |
0.346 |
|
| Show low-probability matches. |